Zanoprima Life Sciences

Zanoprima Life Sciences is a biotechnology company specializing in the development and manufacture of high-purity synthetic nicotine using a proprietary enzymatic process. Their flagship product, SyNic, is a non-tobacco derived nicotine (NTN) that is free from tobacco-specific nitrosamines (TSNAs) and other impurities found in traditional tobacco-extracted nicotine. The company targets the smoking cessation and nicotine replacement therapy (NRT) markets, as well as the next-generation nicotine delivery sector. Beyond consumer products, Zanoprima is exploring the therapeutic potential of synthetic nicotine for neurological conditions such as Alzheimer's and Parkinson's diseases. Their green chemistry approach offers a sustainable and scalable alternative to traditional extraction methods. The company's technology ensures the production of the (S)-isomer of nicotine, which is the biologically active form found in nature.